GeNYC: Genomic Implementation Research in the Diverse Settings and Populations of New York City

Project Summary The promise of genomic medicine to transform healthcare and improve health will not be fully realized until discoveries become relevant to and available for use by diverse populations and their clinicians. As part of the IGNITE II network, we are implementing two prospective randomized pragmatic

genotype-guided clinical trials (GUARDD-US and ADOPT-PGx) to determine the impact of implementing genetic testing on hypertension, depression, and pain therapies. This administrative supplement request is to extend the implementation timeline for these two pragmatic clinical trials by an additional 12 months with cost to allow for completion of GUARDD-US and ADOPT PGx data

analysis, writing up of study results and closeout of all study activities. We expect the successful results from this clinical trial will provide critical evidence needed to drive the implementation of genomic medicine across broad demographics of patient populations.